MedPath

First Participants Randomized in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease

AskBio has announced the randomization of the first participants in its Phase II gene therapy trial targeting Parkinson’s disease, marking a significant step forward in the development of AAV gene therapy technology and therapeutics.

On January 14, 2025, AskBio reached a pivotal milestone in the fight against Parkinson’s disease by randomizing the first participants in its Phase II gene therapy trial. This trial represents a crucial phase in the development of AAV (Adeno-Associated Virus) gene therapy technology and therapeutics, aiming to offer new hope to those affected by Parkinson’s disease. The randomization of participants is a key step in ensuring the trial's integrity and the reliability of its outcomes, as it helps to eliminate bias and ensures that the results are statistically valid. This development underscores AskBio's commitment to advancing gene therapy as a viable treatment option for neurodegenerative diseases.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AskBio's AB-1005 Gene Therapy for Parkinson's Disease Gains FDA RMAT Designation and Enrolls First Phase II Participants

AskBio's AB-1005, a gene therapy for Parkinson's disease, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, potentially expediting its development.
The RMAT designation was supported by positive 36-month Phase Ib data, demonstrating a favorable safety profile and encouraging trends in clinical outcome measures.

BioArctic Doses First Patient in Phase IIa Trial of Exidavnemab for Parkinson's Disease

BioArctic has dosed the first subject in its Phase IIa EXIST trial evaluating exidavnemab, a monoclonal antibody, for the treatment of Parkinson's disease.
The double-blind, placebo-controlled trial will enroll a minimum of 24 participants in Europe to assess the safety and tolerability of exidavnemab.

Denali Therapeutics Initiates Phase 2a Trial of BIIB122 for LRRK2-Associated Parkinson's Disease

Denali Therapeutics has dosed the first participant in its Phase 2a BEACON study of BIIB122, a LRRK2 inhibitor, for LRRK2-associated Parkinson's disease.
The BEACON study will assess the safety and biomarker effects of BIIB122 in approximately 50 participants with LRRK2-related Parkinson's.

Tenaya Therapeutics Doses First Patient in Phase 1b Trial of TN-401 Gene Therapy for ARVC

Tenaya Therapeutics has dosed the first patient in the RIDGE-1 Phase 1b trial evaluating TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
TN-401 is an AAV9-based gene therapy designed to deliver a functional copy of the PKP2 gene directly to heart cells, addressing the underlying genetic cause of ARVC.

ACI-7104 Parkinson's Vaccine Shows Promise in Phase 2 Trial

AC Immune's ACI-7104 vaccine demonstrates safety and tolerability in an early-stage Parkinson's disease Phase 2 trial.
The vaccine effectively stimulates the production of anti-alpha-synuclein antibodies, a key target for Parkinson's treatment.

Vanqua Bio's VQ-101 Shows Promise in Parkinson's Disease with Phase Ib Trial Initiation

Vanqua Bio's VQ-101, an oral small molecule, demonstrated over 75% activation of GCase in healthy volunteers, surpassing the target engagement goal in a Phase Ia trial.
The Phase Ia trial showed VQ-101 to be well-tolerated, with no dose-limiting or serious adverse events, and achieved significant CNS penetration.

Vimgreen Completes Enrollment in Phase 2 Trial of VG081821AC for Parkinson's Disease

Vimgreen Pharmaceuticals has completed enrollment of 150 participants in a Phase 2 trial of VG081821AC for early-to-mid stage Parkinson's disease.
The trial is a 12-week, multicenter, randomized, double-blind, placebo-controlled study evaluating VG081821AC as a monotherapy.

AskBio Initiates Phase 2 Trial of AB-1005 Gene Therapy for Parkinson's Disease

AskBio's REGENERATE-PD, a Phase 2 clinical trial, has begun recruitment to evaluate AB-1005 for moderate-stage Parkinson's disease.
AB-1005 is an investigational adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy.

AskBio's AB-1005 Gene Therapy for Parkinson’s Disease Meets Primary Endpoint in Phase Ib Trial

AskBio's Phase Ib trial for AB-1005, a gene therapy targeting Parkinson’s disease, successfully met its primary endpoint, demonstrating safety and tolerability in all 11 patients over 18 months. The therapy, delivered via one-time bilateral convection-enhanced delivery to the putamen, showed no serious adverse events and exceeded target coverage goals. AskBio plans to present detailed study data in Q2 2024 and initiate a Phase II trial in the first half of 2024.

BIAL R&D Doses First Patient in Phase 2 Trial of BIA 28-6156 for Parkinson's Disease with GBA1 Mutation

BIAL R&D has dosed the first patient in its Phase 2 ACTIVATE study, evaluating BIA 28-6156 for Parkinson's disease patients with a GBA1 gene mutation.
The ACTIVATE study is a multicenter, randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, and tolerability of BIA 28-6156 at two fixed dose levels.

Reference News

[1]
AskBio - AAV Gene Therapy Technology & Therapeutics
askbio.com · Aug 27, 2018

First participants have been randomized in AskBio's Phase II gene therapy trial targeting Parkinson’s disease, marking a...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy